Sumages Pharma Private Limited - Due diligence report

A 360° intelligence report on Sumages Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and …

1985-09-20 Andhra Pradesh, Andhra Pradesh Active Unlisted Active Compliant
Share
SP Sumages Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Sumages Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
70/100
Trust Score
Moderate

Sumages Pharma Private Limited is assessed as Moderate with a Trust Score of 70/100. Sumages Pharma Private Limited is an active private limited indian non-government company incorporated in 1985, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.

Report generated on 18 Jul 2026 from the latest processed filings. Sumages Pharma Private Limited snapshot & full profile →

Financial Health › Neutral
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Good

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
70/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
60/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
50/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
30/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
50/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 30/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 38%).
  • Profitable - internal accruals available.

Charges position: 1 open (1.21 cr) · 9 satisfied (1.02 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Hdfc Bank Limited1 48.0 cr
Ing Vysya Bank Limited1 48.0 cr
A.P. State Financial Corporation6 48.0 cr
Lakshmi General Finance Ltd.1 48.0 cr
The Vysya Bank Ltd.1 48.0 cr
Compliance Score: 60/100 Moderate
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Flagged by authority: EPFO.
  • 1 auditor resignation(s) filed - latest: Rao & Sharma on 2022-07-15.
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
RAGHVA TAYARU ASWANI MANEPALLI 01234567 Director 01/04/2018 6 yrs Approved
SOMESWARA RAO MANEPALLI 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2019)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2022 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 2 transfer(s)

Promoters hold a majority stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 50 · Distress 75
Growth signals & trust indicators
Profit expanded 1.42 year-on-year.
Operating for 40+ years.
Distress signals & risk flags
Revenue declined year-on-year.
1 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence68/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment44/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 1.21 cr already registered.
  • Compliance gaps should be priced into terms.
Investor view55/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
28 Sep 2018
Director ceased
RAGHVA TAYARU ASWANI MANEPALLI
26 Sep 2018
Director ceased
KURISETTI NAGASATYANARAYANA MURTHY
20 Aug 2018
Director appointed
RAGHVA TAYARU ASWANI MANEPALLI (Director)
21 May 2016
Charge created
Hdfc Bank Limited - 1.21 cr
06 Apr 2016
Charge satisfied
Ing Vysya Bank Limited
31 Mar 2016
Share transfer (FY 2016)
21500.00000000 shares to NAGESWARA RAO VENKATA KANAKA
23 Sep 2013
Director ceased
SOMESWARA RAO MANEPALLI
29 May 2013
Director appointed
SOMESWARA RAO MANEPALLI (Director)
Director ceased
VENKATA KANAKA NAGESWARA RAO MANEPALLI
07 May 2012
Director ceased
SURYAMANIKYAM MANEPALLI
26 Mar 2012
Director ceased
NAGA VENKATA KANAKA MANEPALLI SATYANARAYANA MURTHY
23 Feb 2010
Charge satisfied
Lakshmi General Finance Ltd.
09 Jul 2003
Charge satisfied
The Vysya Bank Ltd.
10

Key Observations

Auto-generated from the data above
Revenue declined 2.1x over the last 4 financial year(s).
Debt-to-equity stands at 24% - leverage worth monitoring.
Net worth is positive.
2 active director(s) / partner(s); board looks stable and experienced.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Charli Herbal Products Private Limited U74900UP2011PTC046701 Ghaziabad, Uttar Pradesh, India
Accelerate Social Kount Services Private Limited U74900DL2016PTC292187 East Delhi, Delhi, India
All Well Engineering Private Limited U27210KA1988PTC009122 Bangalore., Karnataka, India
Ganpati Wire Ropes Private Limited U31300MH2001PTC130656 Navi Mumbai, Maharashtra, India
Spectrum Paints & Contracts Private Limited U74120DL2008PTC176105 New Delhi, Delhi, India
Avnish Tradecom Private Limited U52190WB2009PTC133088 Kolkata, West Bengal, India
Amg Buildcon Private Limited U45200DL2006PTC156477 Delhi, Delhi, India
Vijita Techno Private Limited U72900AP2017PTC105292 Vijayawada, Andhra Pradesh, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Sumages Pharma Private Limited before audits and certifications: compliance score 60/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Sumages Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 30/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 50/100, margin trends, ownership structure and peer set for Sumages Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 70/100, distress signals and MSME payment-delay disclosures - know whether Sumages Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Sumages Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Sumages Pharma Private Limited an active company?

Sumages Pharma Private Limited has MCA status “Active” with a compliance score of 60/100 (Moderate).

Is Sumages Pharma Private Limited financially healthy?

Sumages Pharma Private Limited has a Financial Health Score of 50/100 (Moderate) based on its filed financial statements.

Should I do business with Sumages Pharma Private Limited?

Its overall Trust Score is 70/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Sumages Pharma Private Limited?

Promoters hold a majority stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Sumages Pharma Private Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 9 earlier charge(s) stand satisfied.

Is Sumages Pharma Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 60/100 (Moderate).

Is it risky to lend to Sumages Pharma Private Limited?

Its Credit Risk Score is 30/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.